SAN FRANCISCO, Oct. 24, 2017 -- Invuity, Inc. (NASDAQ:IVTY), a leading medical technology company focused on minimal access surgery, today announced that it will release its 2017 third quarter financial results after the market closes on Tuesday, November 7, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Tuesday, November 7, 2017, to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-556-8638 (U.S.) or 1-615-247-0174 (International), Conference ID: 3597539. To listen to the live call via Invuity's website, go to www.invuity.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call in the Events & Presentations section of the website.
About Invuity®
Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The company's patented Intelligent Photonics™ technology delivers enhanced visualization which facilitates surgical precision, efficiency and safety. In addition, the company utilizes comprehensive strategic marketing programs to create stronger institutional partnerships. Clinical applications include women’s health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery. Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic, and general surgery. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
CONTACT:
Company Contact:
Jim Mackaness
Chief Financial Officer
Invuity, Inc.
415-655-2129
Investors:
Mark Klausner
Westwicke Partners
443-213-0501
[email protected]


Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S.
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 



